Last reviewed · How we verify

NCT02984891

Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging

Terminated Last updated 18 March 2021
What this trial tests

trial testing Optical Coherence Tomography (OCT) in Coronary Artery Disease (CAD) in 7 participants. Terminated before completion.

Timeline
6 October 2016
Primary endpoint
27 June 2018
27 June 2018

Quick facts

Lead sponsorColumbia University
StatusTerminated
Study typeOBSERVATIONAL
Enrollment7
Start date6 October 2016
Primary completion27 June 2018
Estimated completion27 June 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Columbia University

Who can join

Eligibility, any sex, with Coronary Artery Disease (CAD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are standardly used and have been extensively studied separately to guide percutaneous coronary intervention and improve long-term outcomes. In this study, the investigators aim to directly compare high-definition IVUS images to OCT in the same patients to determine the differences between each modality as they relate to imaging coronary pathology, with the goal of determining which modality is most appropriate in particular clinical scenarios.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Optical Coherence Tomography (OCT)

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease (CAD)

Currently open trials in the same condition.

Other Columbia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02984891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing